Plain-English translation of NCT07061535 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining Sintilimab and —two newer immunotherapy drugs—with standard chemotherapy can help people with extensive-stage small cell lung cancer. Small cell lung cancer is an aggressive type that spreads quickly, and this study wants to see if adding these newer medications to chemotherapy works better than chemotherapy alone. The goal is to help people live longer and delay their cancer from growing.
Extensive-stage small cell lung cancer is very serious and spreads fast, so patients need more effective treatments. This medication combination aims to boost the immune system's ability to fight cancer cells while chemotherapy attacks them directly, potentially offering better outcomes than current standard treatments.
You likely qualify if…
You likely don't qualify if…
You would receive the treatment combination in 3-week cycles for 4 to 6 months—two of the newer medications given by injection and IV, plus chemotherapy pills and IV infusions on specific days each cycle. After that initial phase, if your cancer responds well, you would continue with the two newer medications as maintenance therapy until your cancer progresses, side effects become too much, or you complete 2 years of treatment. You'll have regular clinic visits for blood work, imaging scans, and check-ins with your doctor to monitor how you're doing.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
China